Editas Medicine announced earlier today that Katrine Bosley has decided to step down from her role as President and CEO, effective March 1. Bosley also resigned from the company’s board. The board has appointed Cynthia Collins, a member of the board, as interim Chief Executive Officer. It also has initiated a search process to identify a permanent CEO and has retained Heidrick & Struggles to assist in its efforts. Bosley will continue with the company in an advisory capacity until the end of 2019. James Mullen, Chairman of the Board of Directors, said, “Editas Medicine has strong positive momentum with the potential to deliver important genome editing medicines to patients around the world. We are fortunate to have someone with Cindy’s proven leadership and significant experience with genomic medicine to take over the day-to-day leadership of Editas Medicine and advance the Company towards its EM22 goals while the CEO search is ongoing.” Bosley commented, “The team at Editas Medicine is making the future of medicine a reality. I’m very proud of them and all they have accomplished. I know they will keep driving forward to make unprecedented medicines to help people with serious diseases, and ones that may truly change patients’ lives. It has been a privilege to be part of Editas Medicine and to help pioneer this field, and I look forward to their continued success.” Shares of Editas Medicine are down 21%, or $5.51, to $20.62 following the news. Shares of peer Crispr Therapeutics (CRSP) are down 12% to $32.70 following a downgrade to Sell at Citi while Intellia Therapeutics (NTLA) is down 8% to $14.04.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.